引用文本：邹沛濡, 林青锋, 王辉, 等. BRAF V600E突变型转移性结直肠癌的最新研究进展[J/CD]. 消化肿瘤杂志（电子版）, 2026, 18(1): 38-41.

作者：邹沛濡，林青锋，王辉，袁紫旭

单位：中山大学附属第六医院结直肠外科，广东 广州 510000

Authors：Zou Peiru, Lin Qingfeng, Wang Hui, Yuan Zixu

Unit：Department of Colorectal Surgery, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, Guangdong, China

摘要：

BRAF基因突变率在转移性结直肠癌中为8%~15%，其中V600E是最常见的突变类型。BRAF V600E突变型结直肠癌通常具有较高的恶性程度，患者术后容易复发转移，对传统化学治疗存在固有耐药性，导致生存期较短、预后差。目前国内外指南均推荐VIC方案（BRAF抑制剂维莫非尼+西妥昔单抗+伊立替康）作为BRAF V600E突变型转移性结直肠癌的标准治疗方案。近年来，免疫治疗在高微卫星不稳定及微卫星稳定的BRAF V600E突变型转移性结直肠癌患者中均展现出潜力。尽管治疗效果不尽相同，但相关临床研究仍在持续探索这一领域，提示免疫治疗有望为这类患者亚群带来更好的临床结局。本文旨在总结BRAF V600E突变型转移性结直肠癌的最新研究进展，以期为临床实践提供参考。

关键词：转移性结直肠癌；BRAF V600E突变；免疫治疗；生存预后

Abstract：

The BRAF mutation occurs in 8% to 15% of metastatic colorectal cancer (mCRC) cases, with the V600E variant being the predominant subtype. Patients harboring the BRAF V600E mutation typically present with aggressive tumor biology, characterized by increased risks of postoperative recurrence and metastasis, inherent resistance to conventional chemotherapy, and consequently, shorter overall survival and poor prognosis. Current national and international clinical guidelines recommend the VIC regimen (vemurafenib, cetuximab, and irinotecan) as a standard treatment for mCRC with BRAF V600E mutation. In recent years, immunotherapy has shown potential in both microsatellite instability-high (MSI-H) and microsatellite stability (MSS) subtypes of BRAF V600E-mutant mCRC. Although treatment efficacy varies, ongoing clinical studies continue to explore this avenue, indicating that immunotherapy may offer improved outcomes for this patient subgroup. This article will systematically review the latest advances in the diagnosis and treatment of BRAF V600E-mutant mCRC, aiming to provide reference for clinical practice.

Key words：Metastatic colorectal cancer; BRAF V600E mutation; Immunotherapy; Prognosis

注：网络优先发布